ImmunityBio Management Team
6 Team Members
ImmunityBio has 6 executives. ImmunityBio's current Chief Financial Officer is David C. Sachs.
Compare ImmunityBio to Competitors
Prokarium is a biopharmaceutical company that focuses on developing vaccination and cancer immunotherapy solutions based on synthetic biology. Its oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases. The company was founded in 2012 and is based in London, U.K.